Business Wire

Limelight’s “2015 State of the User Experience” Report Reveals Who Spends the Most Time Online, User Expectations, Habits and Preferred Devices

Del

What age group is spending the most time online outside of the office each week? If you said Millennials—think a little older … a few decades older.

According to the “2015 State of the User Experience” Report released today by Limelight Networks, Inc., (“Limelight”) (Nasdaq:LLNW), a global leader in digital content delivery, time spent online in the past year has dramatically increased—with 45 percent of respondents spending more than 15 hours a week on their laptop, tablet or phone.

Who is the group making up the majority of these power users? Surprisingly, and possibly counter to popular thought, it’s Baby Boomers—individuals aged 51-69. More than half (51 percent) are online 15 hours/week, as opposed to Millennials—individuals aged 18-33—at just 41 percent.

The Mobile Web, Video and the Importance of a Personal Experience

As the always-connected world continues to expand, so do expectations for the mobile Web—which now has surpassed desktop Web usage according to ComScore. Last year, users were asked if they would be willing to wait longer for a website to load on a mobile device, versus a laptop or desktop, and 44 percent said they would. This year, the results are startlingly different—only 35 percent said they would be willing to wait longer on a mobile device, and nearly 40 percent expect equally fast-loading sites, regardless of if the page is accessed from a mobile device or a laptop/desktop. Clearly, as adoption rates increase, so do expectations for the mobile web.

Other key findings revealed in the report include:

  • Content, not e-commerce, rules the day: Respondents listed “social media sites,” “reading news content” and “watching video content” as their top three online activities, respectively, while “reading news content” was the most popular in 2014. E-commerce finished in 5th place, behind researching products online. There is no question -- users are consuming content more than shopping online.
  • Video is key for Millennials: While social media remains the most popular online activity, Millennials are spending nearly as much time watching online video—which is likely to increase as additional video and streaming options such as live sporting events are made more available.
  • Performance is still key to a great web experience, but surprisingly, patience is an unexpected virtue: Last year, the majority (52 percent) of participants listed a high-performing website as their most critical expectation, with just 41 percent willing to wait more than five seconds for a website to load. While performance was still critical in 2015, patience is on the rise for Internet consumption—this year, 52 percent would wait more than five seconds. Moreover, this year, 33 percent said they would leave a website to buy a product from a competitor if the site loaded too slowly, down from 37 percent last year. Additionally, in 2015, 72 percent would be willing to give the slow-loading site a try in the future, up from 69 percent last year.
  • Users want a personalized experience: Last year, the report stated that the “value of web experience personalization remains to be seen”—as 37 percent indicated they did not want a website to remember them from a previous visit. This year, the results are dramatically different as just 25 percent don’t want a highly-personalized experience.

“Ultimately, consumers want more from their online experience, particularly as the mobile web and video continue their march toward ubiquity,” said Jason Thibeault, senior director of marketing strategy at Limelight. “We have more options than ever—more content, more video, and more shopping. And while patience has increased slightly, people—whether they are Millennials, Gen X or Baby Boomers—all expect a personalized, highly-functioning web experience. If not they will look elsewhere. With the explosion in content, branded entertainment, video and e-commerce, the stakes are higher than ever.”

The “State of the User Experience 2015” report is based on a survey that collected data from 1,302 consumers chosen at random located in the United States, United Kingdom, Canada and Singapore, aged 18-69, who spend more than five hours per week online outside of work. For a complete look, download the report here.

About Limelight
Limelight Networks Inc., (NASDAQ: LLNW), a global leader in digital content delivery, empowers customers to better engage online audiences by enabling them to securely manage and globally deliver digital content, on any device. The company’s award winning Limelight Orchestrate™ platform includes an integrated suite of content delivery technology and services that helps organizations secure digital content, deliver exceptional multi-screen experiences, improve brand awareness, drive revenue, and enhance customer relationships — all while reducing costs. For more information, please visit www.limelight.com, read our blog, follow us on Twitter , Facebook and LinkedIn and be sure to visit Limelight Connect.

Contact information

Press Contact:
fama PR on behalf of Limelight Networks
Ed Harrison, 617-986-5003
limelight@famapr.com
or
Investor Inquiries:
ir@limelight.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial9.12.2017 18:00Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL). Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell l

Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)9.12.2017 17:19Pressemelding

Today, Janssen-Cilag International NV (“Janssen”) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with Imbruvica® (ibrutinib). The extended follow-up data demonstrated that patients treated with ibrutinib earlier (at first relapse) experienced the best clinical outcomes, both in terms of efficacy and tolerability. These data (abstract #151) were presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition in Atlanta, GA.1,2 Ibrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. “Data from this large clinical trial data set with extended follow-up support the early use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma,” said Simo

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom